RB1 and glioblastoma: The results obtained showed a decrease in CDK4, to different extents, in the three GBM cell lines, associated with reduced levels of the phosphorylated form of the RB protein in U87MG and U343MG cells, confirming the inhibitory effect of AdoMet on cell cycle progression.